IP Library › Granted Patent US 12,636,406
Granted Patent B2
US 12,636,406 · App. 18/472,708 · Granted May 26, 2026

Biological prosthesis and methods of production and use

Inventor: Eran Rosines (Salt Lake City, UT)
Assignee: Rosivo LLC
A61L27/3612A61L27/3687A61L27/3695A61L2430/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,636,406
App. No.
18/472,708
Granted
May 26, 2026
Kind
B2
Abstract

Products, processes, compositions, kits, and methods are provided for cartilage-derived implants. The implants can exhibit resistance to enzyme (e.g., collagenase, protease, etc.) digestion compared to the source tissue from which they were derived while still having one or more mechanical properties comparable to the source tissue from which they were derived. The implants can also have a plurality of molecular bridges between molecules of the cartilaginous material. The molecular bridges can connect one or more collagen fibrils and/or/with one or more glycosaminoglycans. The implants can also be treated with cationic detergent, packaged and sterilized with or without additional components, and surgically implanted into subjects.

Claims (79)

1 . A cartilage-derived tissue composition, comprising:

a cartilage-derived body comprising intact extra-cellular matrix and one or more molecular bridges between molecules of the extra-cellular matrix, the one or more molecular bridges selected from the group consisting of:

a molecular bridge formed between amine groups of one or more collagen fibrils;

a molecular bridge formed between hydroxyl groups of one or more glycosaminoglycan molecules;

a molecular bridge formed between a hydroxyl group of a glycosaminoglycan molecule and an amine group of a collagen fibril;

a sulfone-containing bridge; and

a bridge formed from treating the cartilage with a hydrocarbon diol reactive molecule having between 3 and 12 carbon atoms.

2 . The composition of claim 1 , wherein the one or more molecular bridges comprise butanediol.

3 . The composition of claim 1 , wherein the body includes a plurality of molecular bridges, including:

at least one molecular bridge between amine groups of one or more collagen fibrils;

at least one molecular bridge between hydroxyl groups of one or more glycosaminoglycan molecules; and/or

at least one a molecular bridge between a hydroxyl group of a glycosaminoglycan molecule and an amine group of a collagen fibril.

4 . The composition of claim 1 , wherein the body includes a plurality of molecular bridges including at least one hydrocarbon diol-containing bridge having between 3 and 12 carbon atoms and/or at least one sulfone-containing bridge.

5 . The composition of claim 1 , wherein the body includes a plurality of molecular bridges that occupy between 0.000001% and 20% of molecular groups selected from the group consisting of:

amine groups present in the body;

hydroxyl groups present in the body; and

amine and hydroxyl groups present in the body.

6 . A cartilage-derived tissue composition, comprising:

an enzymatically resistant cartilage-derived body comprising intact extra-cellular matrix obtained by treating source cartilage with at least one multifunctional reactive molecule configured to form one or more molecular bridges between molecules of the source cartilage, the one or more molecular bridges selected from the group consisting of:

a molecular bridge formed between amine groups of one or more collagen fibrils;

a molecular bridge formed between hydroxyl groups of one or more glycosaminoglycan molecules;

a molecular bridge formed between a hydroxyl group of a glycosaminoglycan molecule and an amine group of a collagen fibril;

a sulfone-containing bridge; and

a bridge formed from treating the cartilage with a hydrocarbon diol reactive molecule having between 3 and 12 carbon atoms.

7 . The composition of claim 6 , wherein the at least one multifunctional reactive molecule is selected from the group consisting of a molecule comprising more than one and less than 5 reactive epoxide groups; divinyl sulfone; 1,4-butanediol diglycidyl ether (BDDE); 1,2,7,8-diepoxyoctane; and combinations thereof.

8 . The composition of claim 6 , wherein the one or more molecular bridges are not present in the source cartilage prior to treating the source cartilage with the at least one multifunctional reactive molecule.

9 . The composition of claim 6 , wherein the one or more molecular bridges comprise butanediol.

10 . The composition of claim 6 , wherein the body includes a plurality of molecular bridges, including:

at least one molecular bridge between amine groups of one or more collagen fibrils;

at least one molecular bridge between hydroxyl groups of one or more glycosaminoglycan molecules; and

at least one a molecular bridge between a hydroxyl group of a glycosaminoglycan molecule and an amine group of a collagen fibril.

11 . The composition of claim 6 , wherein the body includes a plurality of molecular bridges including at least one hydrocarbon diol-containing bridge having between 3 and 12 carbon atoms and/or at least one sulfone-containing bridge.

12 . The composition of claim 6 , wherein the body includes a plurality of molecular bridges that occupy between 0.000001% and 20% of molecular groups selected from the group consisting of:

amine groups present in the body;

hydroxyl groups present in the body; and

amine and hydroxyl groups present in the body.

13 . The composition of claim 6 , wherein the body is resistant to at least one of cellular infiltration and enzymatic digestion as compared to the source cartilage prior to treating the source cartilage with the at least one multifunctional reactive molecule.

14 . The composition of claim 6 , wherein the body has or exhibits one or more properties or characteristics selected from the group consisting of:

resistance against enzymatic digestion compared to the source cartilage;

biocompatibility for human implantation;

glycosaminoglycan content within 25% of the glycosaminoglycan content of the animal source cartilage;

type II collagen content within 25% of the type II collagen content of the animal source cartilage;

a mechanical property value substantially the same as a mechanical property value of the source cartilage;

a mechanical property value within 25% of a mechanical property value of the source cartilage; and

a mechanical property value within one standard deviation of an average mechanical property value of the source cartilage.

15 . The composition of claim 14 , wherein the mechanical property value is selected from the group consisting of a yield stress value, a yield strain value, a yield strain at break value, a compressive yield stress value, a compressive yield strain value, a compressive yield strain at break value, a Young's modulus value, a compressibility value, an elasticity value, an instantaneous stiffness value, a tensile strength value, a tensile strain value, a coefficient of friction value, a resilience value, and a shock absorption value.

16 . The composition of claim 6 , wherein the source cartilage is derived from an animal explant.

17 . A cartilage-derived tissue composition, comprising:

a cartilage-derived body comprising intact extra-cellular matrix obtained by treating source cartilage with at least one multifunctional reactive molecule is selected from the group consisting of a molecule comprising more than one and less than 5 reactive epoxide groups; divinyl sulfone; 1,4-butanediol diglycidyl ether (BDDE); 1,2,7,8-diepoxyoctane; and combinations thereof.

18 . The composition of claim 17 , wherein the body comprises one or more molecular bridges between molecules of the extra-cellular matrix, the one or more molecular bridges selected from the group consisting of:

a bridge formed from treating the cartilage with a hydrocarbon diol reactive molecule having between 3 and 12 carbon atoms;

a sulfone-containing bridge;

a molecular bridge formed between amine groups of one or more collagen fibrils;

a molecular bridge formed between hydroxyl groups of one or more glycosaminoglycan molecules; and

a molecular bridge formed between a hydroxyl group of a glycosaminoglycan molecule and an amine group of a collagen fibril.

19 . The composition of claim 17 , wherein the one or more molecular bridges are not present in the source cartilage prior to treating the source cartilage with the at least one multifunctional reactive molecule.

20 . The composition of claim 17 , wherein the one or more molecular bridges comprise butanediol.

21 . The composition of claim 17 , wherein the body includes a plurality of molecular bridges, including:

at least one molecular bridge between amine groups of one or more collagen fibrils;

at least one molecular bridge between hydroxyl groups of one or more glycosaminoglycan molecules; and

at least one a molecular bridge between a hydroxyl group of a glycosaminoglycan molecule and an amine group of a collagen fibril.

22 . The composition of claim 17 , wherein the body includes a plurality of molecular bridges including at least one hydrocarbon diol-containing bridge having between 3 and 12 carbon atoms and/or at least one sulfone-containing bridge.

23 . The composition of claim 17 , wherein the body includes a plurality of molecular bridges that occupy between 0.000001% and 20% of molecular groups selected from the group consisting of:

amine groups present in the body;

hydroxyl groups present in the body; and

amine and hydroxyl groups present in the body.

24 . The composition of claim 17 , wherein the body is resistant to at least one of cellular infiltration and enzymatic digestion as compared to the source cartilage prior to treating the source cartilage with the at least one multifunctional reactive molecule.

25 . The composition of claim 17 , wherein the body has or exhibits one or more properties or characteristics selected from the group consisting of:

resistance against enzymatic digestion compared to the source cartilage;

biocompatibility for human implantation;

glycosaminoglycan content within 25% of the glycosaminoglycan content of the animal source cartilage;

type II collagen content within 25% of the type II collagen content of the animal source cartilage;

a mechanical property value substantially the same as a mechanical property value of the source cartilage;

a mechanical property value within 25% of a mechanical property value of the source cartilage; and

a mechanical property value within one standard deviation of an average mechanical property value of the source cartilage.

26 . The composition of claim 25 , wherein the mechanical property value is selected from the group consisting of a yield stress value, a yield strain value, a yield strain at break value, a compressive yield stress value, a compressive yield strain value, a compressive yield strain at break value, a Young's modulus value, a compressibility value, an elasticity value, an instantaneous stiffness value, a tensile strength value, a tensile strain value, a coefficient of friction value, a resilience value, and a shock absorption value.

27 . The composition of claim 17 , wherein the source cartilage is derived from:

an intact extra-cellular matrix structure comprising glycosaminoglycans (GAGs) and/or (type II) collagen; and/or

an animal explant, wherein the animal explant is optionally selected from the group consisting of septal cartilage, auricular cartilage, costal cartilage, and articular cartilage, and wherein the animal optionally selected from the group consisting of pig, horse, cow, canine, human, a non-human animal genetically deficient in expression of galactose-alpha-1,3-galactose, a non-human animal that has been genetically altered to express one or more human proteins, and a non-human animal that has been genetically altered to express one or more human proteins and that is genetically deficient in expression of galactose-alpha-1,3-galactose.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2023
From: ROSINES, ERAN
To: ROSIVO LLC
Reel/Frame 065016/0062 →
Continuity (5)
Continuation 17069397 · Oct 13, 2020
Continuation 15994740 · May 31, 2018
Division 14477797 · Sep 4, 2014
Provisional Application 61875122 · Sep 9, 2013
Related Publication 20240016980A1 · Jan 18, 2024
References Cited (59)
US 3314861A · Tadahiko · 1967 [cited by applicant]
US 5035715A · Smestad et al. · 1991 [cited by applicant]
US 5128326A · Balazs et al. · 1992 [cited by applicant]
US 5782915A · Stone · 1998 [cited by applicant]
US 5989498A · Odland · 1999 [cited by applicant]
US 6117979A · Hendriks et al. · 2000 [cited by applicant]
US 6166184A · Hendriks et al. · 2000 [cited by applicant]
US 6203755B1 · Odland · 2001 [cited by applicant]
US 6734018B2 · Wolfinbarger, Jr. et al. · 2004 [cited by applicant]
US 7053051B2 · Hendrikcs et al. · 2006 [cited by applicant]
US 8697442B2 · Hendriks et al. · 2014 [cited by applicant]
US 8901078B2 · Mezger et al. · 2014 [cited by applicant]
US 9072819B2 · Hendriks et al. · 2015 [cited by applicant]
US 9220808B2 · Mezger et al. · 2015 [cited by applicant]
US 9399084B2 · Mezger et al. · 2016 [cited by applicant]
US 9592320B2 · Mezger et al. · 2017 [cited by applicant]
US 10016528B2 · Rosines · 2018 [cited by examiner]
US 10561762B2 · Rosines · 2020 [cited by applicant]
US 10611822B2 · Mezger et al. · 2020 [cited by applicant]
US 10814035B2 · Rosines · 2020 [cited by examiner]
US 11801330B2 · Rosines · 2023 [cited by examiner]
US 20080077251A1 · Chen et al. · 2008 [cited by applicant]
US 20090012627A1 · Claesson et al. · 2009 [cited by applicant]
US 20100174374A1 · Haines · 2010 [cited by applicant]
US 20110195107A1 · Min et al. · 2011 [cited by applicant]
US 20120282226A1 · Ayares et al. · 2012 [cited by applicant]
US 20130030526A1 · Mezger et al. · 2013 [cited by applicant]
US 20160000970A1 · Rosines · 2016 [cited by applicant]
EP 0640647A2 · 1995 [cited by applicant]
WO 1996025961A1 · 1996 [cited by applicant]
WO 1997017430A1 · 1997 [cited by applicant]
WO 2006026325A2 · 2006 [cited by applicant]
WO 2010108945A1 · 2010 [cited by applicant]
WO 2013036568A1 · 2013 [cited by applicant]
Alexander Florian Elsaesser et al., In Vitro Cytotoxicity and In Vivo Effects of a Decellularized Xenogeneic Collagen Scaffold in Nasal Cartilage Repair, Tissue Engineering: Part A, vol. 20, No. 11 and 12, 2014, pp. 166… [cited by applicant]
Raymond Zeeman et al., The Kinetics of 1,4-Butanediol Diglycidyl Ether Cross/inking of Dermal Sheep Collagen, J. Biomed Mater Res., vol. 15, No. 51 (4), Sep. 2000, pp. 541-548. [cited by applicant]
Damink et al. “Glutaraldehyde as a crosslinking agent for collagen-based biomaterials,” Journal of Materials Science: Materials in Medicine. Aug. 1995, vol. 6, pp. 460-472 entire document. [cited by applicant]
Kaukinen et al. “Destructive Testing of Articular Cartilage in Compression-Effect of Collagen Network,” 2005, 51 st Annual Meeting of the Orthopaedic Research Society, Poster No. 1691, available at http://www.ors.or_g/t… [cited by applicant]
Hovakimyan et al. “Collagen cross-linking: current status and future directions,” J Ophthalmol. Jan. 12, 2012 (Jan. 12, 2012), Article ID 406850, pp. 1-12. entire document. [cited by applicant]
Wong et al. “Stepwise solubilization-based antingen removal for xenogeneic scaffold generation in tissue engineering,” Acta Biomater. Jan. 12, 2013 (Jan. 12, 2013), vol. 9, pp. 6492-6501. entire document. [cited by applicant]
Aparecida Da Silva Aquino, K. “Chapter 9: Sterilization by Gamma Irradiation,” Mar. 21, 2012 (Mar. 21, 2012). Gamma Radiation, Edited by Adrovic, pp. 171-206, available at http://cdn.intechopen.com/pdfs-wm/32842.pdf ent… [cited by applicant]
Ali, Sy “The Degradation of Cartilage Matrix by an Intracellular Protease” Biochem. J. (1964), 93, 611-618. [cited by applicant]
Cavallito CJ “Quaternary ammonium salts—advances in chemistry and pharmacology since 1960” Progress in Drug Research, (B. Berde et al.(ed.)), pp. 267-373. [cited by applicant]
Feng Yu et al. “An interpenetrating HAIG/CS biomimic hydrogel via Diels-Alder click chemistry for cartilage tissue engineering”, Carbohydrate Polymers, Apr. 26, 2013, pp. 188-195, vol. 97, No. 1, Applied Science Publish… [cited by applicant]
Henrique V. Almeida et al. “Controlled release of transforming growth factor-133 from cartilage-extra-cellular-matrix-derived scaffolds to promote chondrogenesis of human-joint-tissue-derived stem cells”, Acta Biomateri… [cited by applicant]
Decision to Grant received for European Patent Application No. 14841988, mailed on Oct. 10, 2019, 2 pages. [cited by applicant]
European Search Report received for EP Patent Application No. 14841988, mailed on Apr. 28, 2017, 8 pages. [cited by applicant]
Feng Yu et al. “An interpenetrating HA/G/CS biomimic hydrogel via Diels-Alder click chemistry for cartilage tissue engineering”, Carbohydrate Polymers, Apr. 26, 2013, pp. 188-195, vol. 97, No. 1, Applied Science Publish… [cited by applicant]
Henrique V. Almeida et al. “Controlled release of transforming growth factor-ß3 from cartilage-extra-cellular-matrix-derived scaffolds to promote chondrogenesis of human-joint-tissue-derived stem cells”, Acta Biomateria… [cited by applicant]
Hermansson, M. et al, “Proteomic Analysis of Articular Cartilage Shows Increased Type II Collagen Synthesis in Osteoarthritis and Expression of Inhibin .Beta.-A (Activin A), a Regulatory Molecule for Chondrocytes”, JBC,… [cited by applicant]
Intention to grant received for European Patent Application No. 14841988, mailed on Apr. 23, 2019, 6 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2014/054386, mailed on Mar. 24, 2016, 16 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2014/054386, mailed on Dec. 31, 2014, 19 pages. [cited by applicant]
Notice of Allowance received for U.S. Appl. No. 14/477,797, mailed on Jan. 18, 2018. [cited by applicant]
Office Action received for European Patent Application No. 14841988, mailed on Apr. 25, 2018, 6 pages. [cited by applicant]
Office Action received for U.S. Appl. No. 14/477,797, mailed on Jan. 3, 2017. [cited by applicant]
Office Action received for U.S. Appl. No. 14/477,797, mailed on Jul. 5, 2016. [cited by applicant]
Office Action received for U.S. Appl. No. 14/477,797, mailed on Sep. 22, 2017. [cited by applicant]
U.S. Appl. No. 61/875,122, filed Sep. 9, 2013, Rosines. [cited by applicant]